Giving (Bits of) Your Self to Medicine

Author | Raymond De Vries

Illustration by Marco Melgrati

You are sitting in the hospital, waiting for a checkup or perhaps to have a mole removed. In filling out the paperwork — What medications you are taking? Are your emergency contacts up to date? — you encounter a question about what is to be done with "excess tissues or specimens" that may be removed during diagnosis or treatment. Are you willing to donate these leftover bits of yourself (stripped of your name, of course) for medical research? 

If you are inclined to answer, "Sure, why not?" you will join the majority of Americans who agree to donate. And hey, it may be your donation that leads to the long-sought cure for cancer! 

On the other hand, the request to use part of your body for research may give you pause. What, exactly, will be done with your donation? Can the biobank guarantee that your genetic information will not be shared with your insurance company? Will your donation be used to patent a new drug that will be sold back to you at an exorbitant price? 

These questions may soon become a lot more real for many of us. 

Progress in science and medicine depends on public trust in the research enterprise. If scientists violate that trust they risk losing public support — and funding — for their work. 

In January 2015, President Obama announced his Precision Medicine Initiative, or PMI, asking for $215 million to move medical care from a "one-size-fits-all" approach to one that tailors treatments to each person's genetic make-up. Obama sees precision medicine as "one of the greatest opportunities for new medical breakthroughs that we have ever seen," allowing doctors to provide "the right treatments at the right time, every time, to the right person." 

What does this have to do with you and your decision to donate your blood and/or tissue to medical research? A critical piece of Obama's PMI, which is now being implemented, is the creation of a "voluntary national research cohort" of 1 million people who will provide the "data" researchers need to make this big jump in medical care. Yes, among other things, those "data" include bits of blood and tissue that will help scientists find the link between genes, illness and treatments. 

Those who are skeptical of the PMI have pointed to several problems with the plan, but none have focused on the most fundamental question: How will we get 1 million people to donate pieces of themselves to research? Recognizing that there may be some reluctance to donate, the drafters of the initiative bent over backwards to assure future donors that their privacy will be "rigorously protected." 

But privacy is not the only worry for donors. We at the Center for Bioethics and Social Sciences in Medicine — together with colleagues from the Center for Ethics and Humanities in the Life Sciences at Michigan State University — asked the American public about their willingness to hand over bits of themselves to researchers. Data from our national survey, published in the Journal of the American Medical Association, reveal that while most Americans are willing to donate to biobanks, they have serious concerns about how we ask for their consent and about how their donations may be used in future research. 

We asked our respondents — a sample representative of the U.S. population — if they would be willing to donate to a biobank using the current method of "blanket consent" where donors are asked to agree that their tissue can be used for any research study approved by the biobank, "without further consent from me." A healthy majority agreed. But when asked if they would still be willing to give blanket consent if they were told that their specimens might be used "to develop patents and earn profits for commercial companies" that number dropped significantly. Willingness to donate also dropped when respondents were told that their specimen might be used to create bioweapons or to develop more safe and effective abortion methods. 

Should we take these moral concerns seriously? Progress in science and medicine depends on public trust in the research enterprise. If scientists violate that trust they risk losing public support — and funding — for their work. The Havasupai tribe of Arizona, for instance, banished all researchers after learning that DNA donated by tribe members for research on the genetics of diabetes was also used, without permission, for a study that undermined the tribal story of its origins by tracing the migration of Havasupai ancestors. The Havasupai are not unique. In our sample we found that lack of trust in scientists and scientific research was the strongest predictor of unwillingness to donate to a biobank. 

When you are sitting in the waiting room, contemplating the decision to donate some of your self, you should be assured that doing so will not violate your sense of what is good or moral. The "Proposed Privacy and Trust Principles" issued by the PMI in 2015 are a hopeful sign. They call for transparency about "how [participant] data will be used, accessed and shared," including "the types of studies for which the individual's data may be used." The PMI soon will be asking us to donate bits of ourselves, and, if these principles are honored, they will go a long way toward building the trust that biobanks, and precision medicine, need to succeed. 

Raymond De Vries, Ph.D., is co-director of U-M's Center for Bioethics and Social Sciences in Medicine, and a professor in the Department of Learning Health Sciences. 

More Articles About: Genetics gray matters Research biobanks precision medicine initiative center for bioethics and social sciences in medicine Data
Featured News & Stories Health Lab Podcast in brackets with a background with a dark blue translucent layers over cells
Health Lab Podcast
Addressing health care inequality
An expert on racial and ethnic differences in health care and health outcomes offers recommendations as part of a national committee.
woman smiling with man in michigan gear selfie
Health Lab
Getting ahead of aortic disease
Patient bypasses a life threatening aortic aneurysm with the help of Michigan Medicine's genetic counseling and a streamlined cardiac referral program.
Health Lab Podcast in brackets with a background with a dark blue translucent layers over cells
Health Lab Podcast
Presenting: The Fundamentals
Today on Health Lab, we are sharing an episode of The Fundamentals, another podcast from the Michigan Medicine Podcast Network that just launched its second season earlier this month. On this episode of The Fundamentals: "Cannabis and psychedelics: stigmatized substances or powerful therapeutics?" Dr. Kevin Boehnke talks about cannabis, psychedelics, and the increasing body of evidence for their legitimization as therapeutics.
The Fundamentals Podcast Hero Card Final 1800 x 1350
The Fundamentals
Treating Diabetes & Weight: The Ozempic & Wegovy Effect
Today on The Fundamentals, our guest Dr. Martin Myers, Director of the U-M Elizabeth Weiser Caswell Diabetes Institute, discusses diabetes research in the context of Ozempic, Wegovy, and other drugs that are changing how people think about weight loss. You can learn more about Dr. Myers here, and you can follow the department of molecular and integrative physiology @UMPhysiology on X.
The Fundamentals Podcast Hero Card Final 1800 x 1350
The Fundamentals
Can AI Make Us Healthier Humans?
Dr. Jody Platt. She is an Associate Professor of Learning Health Sciences at the University of Michigan Medical School. Trained in medical sociology and health policy, her research focuses on issues at the intersection of informatics and ethics. She is interested in understanding what makes data-driven health trusted, and the pathways for earning, achieving, and sustaining trust across stakeholders. Dr. Platt is the Academy Health and ABIM Foundation Senior Scholar in Residence advising on issues of measuring and building trust.
The Fundamentals Podcast Hero Card Final 1800 x 1350
The Fundamentals
From Patients to Progress: Advancing Autoimmune Research
Today on The Fundamentals, our guest is Dr. Michelle Kahlenberg, an Associate Professor of Internal Medicine and Dermatology, the Giles Bole and Dorothy Mulkey Research Professor of Rheumatology and the Vice Chair for Basic and Translational Research in Internal Medicine. Her clinical work is centered on the care of patients with lupus, including those with refractory skin disease. In addition to running her lab, she's an active member of the Immunology Training Program and has received national recognition for her research.